Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | IDH1 | O75874 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189291 | 1.00 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL4189285 | 1.00 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL3637332 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9743493 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9557087 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9743484 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL3773685 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL19814964 | 0.98 | NAAA (0.46) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL7495438 | 0.98 | NAAA (0.46) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL15443176 | 0.95 | NAAA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107032992-A | A kind of synthetic method of (R) 4 (tert-butoxy) 2 (cyclopentyl-methyl) 4 ketobutyric acid | 华东师范大学 | 2017-08-11 | — | — | CN | claimed |
| US-9771372-B2 | Compounds useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2017-09-26 | — | — | US | disclosed |
| CN-107032992-A | A kind of synthetic method of (R) 4 (tert-butoxy) 2 (cyclopentyl-methyl) 4 ketobutyric acid | 华东师范大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-07-20 | — | — | US | disclosed |
| EP-2991990-B1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2991990-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015177367-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2015-11-26 | — | — | WO | disclosed |
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2785348-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-10-08 | — | — | EP | disclosed |
| EP-1210330-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-1169031-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2002-01-09 | — | — | EP | disclosed |
| US-6316633-B1 | CARTILAGE PROTECTIVE AGENTS AND USEFUL IN THE THERAPY AND PROPHYLAXIS OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-11-13 | — | — | US | disclosed |
| US-6197995-B1 | INTERMEDIATES FOR CARTILAGE PROTECTIVE AGENTS USEFUL IN TREATMENT AND PREVENTION OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2001010835-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| EP-1052249-A1 | Process for the preparation of hydroxamic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000061134-A1 | ANTIMICROBIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-19 | — | — | WO | disclosed |
| US-5952507-A | Process for manufacture of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-14 | — | — | US | disclosed |
| EP-0911324-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-28 | — | — | EP | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | LMNA 1584/4885MAPK1 487/4885SMN1; SMN2 383/4885 |
| US-20140323476-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, HAMP | LMNA 3374/4885MAPK1 3164/4885SMN1; SMN2 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.